A groundbreaking advancement in peanut allergy treatment has emerged with the FDA’s recent approval of a new oral immunotherapy drug. This therapy, designed for children aged 4 to 17, works by gradually desensitizing the immune system to peanut proteins. Clinical trials showed that nearly 70% of participants could tolerate up to 600 mg of peanut protein—equivalent to about two peanuts—after a year of treatment. Unlike previous options, which only mitigated reactions, this drug aims to provide long-term tolerance.
Experts caution that the treatment must be administered under strict medical supervision due to the risk of severe allergic reactions during the desensitization process. However, this development offers hope to millions of families managing life-threatening peanut allergies, potentially reducing the constant fear of accidental exposure.
You Might Be Interested In:
- How to Stop Diarrhea Fast: Methods & What to Avoid
- 8 Drinks for When You Have Diarrhea
- Researchers Identify Key Immune Cells Behind Peanut Allergy Prevention
